ImmunoPrecise Antibodies Ltd. (IPA)
NASDAQ: IPA · Real-Time Price · USD
1.970
-0.020 (-1.01%)
Aug 14, 2025, 11:32 AM - Market open
ImmunoPrecise Antibodies Balance Sheet
Financials in millions CAD. Fiscal year is May - April.
Millions CAD. Fiscal year is May - Apr.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Apr '25 Apr 30, 2025 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 | Apr '21 Apr 30, 2021 | 2016 - 2020 |
| Cash & Equivalents | 10.67 | 3.46 | 8.28 | 29.97 | 41.76 | Upgrade
|
| Cash & Short-Term Investments | 10.67 | 3.46 | 8.28 | 29.97 | 41.76 | Upgrade
|
| Cash Growth | 208.33% | -58.23% | -72.37% | -28.24% | 1502.42% | Upgrade
|
| Accounts Receivable | 4.66 | 4.07 | 3.88 | 3.13 | 3.63 | Upgrade
|
| Other Receivables | 0.14 | 0.41 | 0.54 | 0.28 | 0.49 | Upgrade
|
| Receivables | 4.81 | 4.48 | 4.42 | 3.41 | 4.12 | Upgrade
|
| Inventory | 2.1 | 2.14 | 2.06 | 1.62 | 1.2 | Upgrade
|
| Prepaid Expenses | 1.19 | 1.41 | 2.04 | 2.48 | 1.78 | Upgrade
|
| Total Current Assets | 18.75 | 11.49 | 16.79 | 37.47 | 48.86 | Upgrade
|
| Property, Plant & Equipment | 15.76 | 16.7 | 10.39 | 3.56 | 4.02 | Upgrade
|
| Long-Term Investments | - | - | 0.12 | 0.14 | 0.11 | Upgrade
|
| Goodwill | 8.23 | 7.69 | 19.17 | 19.64 | 7.78 | Upgrade
|
| Other Intangible Assets | 1.07 | 23.56 | 30.91 | 32.37 | 6.03 | Upgrade
|
| Long-Term Deferred Charges | - | - | 0.02 | 0.03 | 0.03 | Upgrade
|
| Other Long-Term Assets | 0.63 | 0.56 | 0.42 | 0.45 | 0.13 | Upgrade
|
| Total Assets | 44.44 | 59.99 | 77.81 | 93.65 | 66.96 | Upgrade
|
| Accounts Payable | 5.28 | 4.07 | 2.49 | 4.37 | 1.81 | Upgrade
|
| Accrued Expenses | 0.48 | 0.85 | 0.9 | 0.43 | 1.34 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | - | 1.31 | - | Upgrade
|
| Current Portion of Leases | 1.85 | 1.56 | 1.12 | 0.99 | 0.99 | Upgrade
|
| Current Income Taxes Payable | - | - | - | 0.42 | 0.33 | Upgrade
|
| Current Unearned Revenue | 1.09 | 1.35 | 0.98 | 1.03 | 1.11 | Upgrade
|
| Other Current Liabilities | 0.31 | 0.28 | 0.44 | 0.74 | 0.5 | Upgrade
|
| Total Current Liabilities | 9.01 | 8.12 | 5.92 | 9.29 | 6.07 | Upgrade
|
| Long-Term Debt | - | - | - | - | 1.53 | Upgrade
|
| Long-Term Leases | 11.55 | 12.12 | 6.15 | 0.47 | 0.94 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 0.25 | 4.07 | 7.66 | 8.11 | 1.49 | Upgrade
|
| Other Long-Term Liabilities | - | - | 0.28 | 0.5 | - | Upgrade
|
| Total Liabilities | 20.82 | 24.31 | 20.01 | 18.36 | 10.04 | Upgrade
|
| Common Stock | 136.37 | 119.77 | 117.47 | 114.56 | 80.1 | Upgrade
|
| Additional Paid-In Capital | 12.83 | 12.39 | 10.8 | 9.63 | 7.2 | Upgrade
|
| Retained Earnings | -128.79 | -98.56 | -73.09 | -46.53 | -29.82 | Upgrade
|
| Comprehensive Income & Other | 3.22 | 2.08 | 2.63 | -2.38 | -0.56 | Upgrade
|
| Total Common Equity | 23.63 | 35.68 | 57.8 | 75.29 | 56.92 | Upgrade
|
| Shareholders' Equity | 23.63 | 35.68 | 57.8 | 75.29 | 56.92 | Upgrade
|
| Total Liabilities & Equity | 44.44 | 59.99 | 77.81 | 93.65 | 66.96 | Upgrade
|
| Total Debt | 13.4 | 13.68 | 7.27 | 2.77 | 3.46 | Upgrade
|
| Net Cash (Debt) | -2.74 | -10.22 | 1.01 | 27.2 | 38.3 | Upgrade
|
| Net Cash Growth | - | - | -96.28% | -28.99% | - | Upgrade
|
| Net Cash Per Share | -0.08 | -0.40 | 0.04 | 1.38 | 2.32 | Upgrade
|
| Filing Date Shares Outstanding | 46.15 | 27.3 | 24.94 | 24.84 | 19.23 | Upgrade
|
| Total Common Shares Outstanding | 46.15 | 26.94 | 25.05 | 24.48 | 19.17 | Upgrade
|
| Working Capital | 9.74 | 3.36 | 10.87 | 28.18 | 42.79 | Upgrade
|
| Book Value Per Share | 0.51 | 1.32 | 2.31 | 3.07 | 2.96 | Upgrade
|
| Tangible Book Value | 14.33 | 4.43 | 7.73 | 23.29 | 43.11 | Upgrade
|
| Tangible Book Value Per Share | 0.31 | 0.16 | 0.31 | 0.95 | 2.24 | Upgrade
|
| Machinery | 6 | 5.39 | 6.81 | 5.19 | 4.56 | Upgrade
|
| Construction In Progress | 0.11 | 0.03 | - | 0.14 | - | Upgrade
|
| Leasehold Improvements | 0.34 | 0.31 | 0.63 | 0.35 | 0.35 | Upgrade
|
Updated Jul 29, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.